Retinis Pigmentosa Market is segmented By Inheritance Type (Autosomal Dominant, Autosomal Recessive, X-linked), By Disease Type (Syndromic Retinitis Pigmentosa, Non-Syndr ....
Market Size in USD
CAGR6.2%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 6.2% |
Market Concentration | High |
Major Players | Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, GenSight Biologics |
The Retinitis Pigmentosa Market is estimated to be valued at USD 510.1 million in 2024 and is expected to reach USD 991.3 million by 2031, growing at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031. Retinitis pigmentosa is a group of genetic disorders that causes vision loss or blindness. It is estimated that this disease affects nearly 2 million people globally.
The market is expected to grow at a steady rate owing to the rising prevalence of the disease and lack of any definitive cure. Currently available treatment options are limited to drugs that can only help slow down the degeneration process. However, gene therapy and stem cell therapy present promising opportunities and their development is expected to drive the market during the forecast period if found successful in clinical trials and approved for commercialization.